Connect Biopharma Holdings Limited
CNTB
$0.7901
-$0.0099-1.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.03M | 25.07M | 24.12M | 12.06M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.03M | 25.07M | 24.12M | 12.06M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 26.03M | 25.07M | 24.12M | 12.06M | -- |
| SG&A Expenses | 19.23M | 17.31M | 15.39M | 15.72M | 16.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | -601.00K | -1.20M | -601.00K | 0.00 |
| Total Operating Expenses | 48.49M | 51.17M | 53.86M | 61.46M | 69.06M |
| Operating Income | -22.45M | -26.10M | -29.75M | -49.40M | -69.06M |
| Income Before Tax | -15.41M | -19.64M | -23.87M | -42.93M | -61.99M |
| Income Tax Expenses | 223.00K | 169.50K | 116.00K | 118.00K | 120.00K |
| Earnings from Continuing Operations | -15.63 | -19.81 | -23.98 | -43.04 | -62.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.63M | -19.81M | -23.98M | -43.04M | -62.11M |
| EBIT | -22.45M | -26.10M | -29.75M | -49.40M | -69.06M |
| EBITDA | -21.79M | -25.42M | -29.05M | -48.70M | -68.34M |
| EPS Basic | -0.28 | -0.36 | -0.44 | -0.78 | -1.13 |
| Normalized Basic EPS | -0.17 | -0.22 | -0.26 | -0.48 | -0.70 |
| EPS Diluted | -0.28 | -0.36 | -0.44 | -0.79 | -1.13 |
| Normalized Diluted EPS | -0.17 | -0.22 | -0.26 | -0.48 | -0.70 |
| Average Basic Shares Outstanding | 220.85M | 220.65M | 220.45M | 220.36M | 220.27M |
| Average Diluted Shares Outstanding | 221.67M | 221.47M | 221.27M | 220.77M | 220.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |